ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

The Effects of Thymopentin on the Development of SLE-Like Syndrome in the MRL/lpr-lpr Mouse (1994)

NICOLETTI, F. ; ZACCONE, P. ; MAGRO, G. ; [et al.]

Oxford, UK : Blackwell Publishing Ltd

Scandinavian journal of immunology 40 (1994), S. 0

add to mindlist on the mindlist

Details

ISSN: 1365-3083

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: Thymopentin (TP-5) is a synthetic pentapeptide that corresponds to the active 32–36 amino acid sequence of the thymic hormone thymopoietin, of which it retains all the immunomodulatory properties. In this study, we have evaluated the effects of long term prophylactic treatment with TP-5 on the clinical, immunological and histological parameters of the SLE-like syndrome that spontaneously occurs in MRL/lpr-lpr (MRL-lpr) mice. TP-5., administered (s. c.) to these mice at the doses of 1, 10 and 100mg/kg. was given daily, five times a week, from the 9th to the 26th weeks of life. The prophylactic treatment with TP-5 prolonged in a clear dose-dependent fashion the lifespan of MRL-lpr mice as compared with PBS-treated control mice, and the effect reached statistical significance at the doses of 10 and 100mg/kg. In parallel ex vivo studies., this chnical effect was associated with multiple profound modifications of the immune system including: (i) the reduction of the spontaneous and Con A-induced release of interleukin-4 (IL-4); (ii) the increased secretion of interferon-γ (IFN-γ) and IL-6 upon polyclonal mitogenic stimulation, and (iii) the amelioration of the defective Con A-induced lympho-proliferative response. In contrast, although the drug diminished the severity of proteinuHa in MRL-lpr mice, it neither reduced histological signs of lupus nephritis nor diminished the serum titres of antinative DNA and anti-histone autoantibodies. These results indicate that TP-5 displayed powerful immunomodulatory activities in a well known model of human SLE.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1111/j.1365-3083.1994.tb03503.x

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study (1997)

Bonaduce, D. ; Canonico, V. ; Petretta, M. ; [et al.]

Springer

European journal of clinical pharmacology 53 (1997), S. 95-100

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: Key words Felodipine ER ; Hypertension

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Abstract Objective: This double-blind, placebo-controled randomized study was designed to compare the antihypertensive effect and tolerability of extended-release felodipine and slow-release nifedipine retard in elderly hypertensive patients. Methods: Thirty patients of both sexes (mean age 71 years) with mild to moderate essential hypertension were recruited from our hypertension outpatient clinic. After a 2-week placebo period, felodipine extended-release (felodipine ER), 10 mg once daily, nifedipine slow-release retard (nifedipine SR), 20 mg twice daily or placebo were administered to each patient for 2 weeks according to a 3 × 3 latin-square design. At the end of each treatment period, the patients underwent 24-h noninvasive blood pressure monitoring. Results: All of the patients completed the trial and no serious adverse experience was reported. In comparison with placebo, felodipine and nifedipine decreased mean 24-h diastolic blood pressure by 6.7 and 4.3 mmHg, respectively, with no significant difference between the two drugs. Mean 24-h systolic blood pressure also decreased after felodipine and nifedipine, with no difference between the two drugs. Both drugs reduced blood pressure variability, lowering the 24-h mean standard deviation of mean hourly blood pressure values. The trough:peak ratio for felodipine was 80% for systolic and 75% for diastolic blood pressure. Conclusion: Felodipine ER once daily lowers blood pressure in elderly hypertensives and is as effective as nifedipine SR twice daily. The high trough:peak ratio suggests that the dose and the between-dose interval of felodipine provides adequate therapeutic coverage.